Thu, Oct 30, 2014, 12:22 PM EDT - U.S. Markets close in 3 hrs 38 mins

Recent

% | $
Quotes you view appear here for quick access.

Alnylam Pharmaceuticals, Inc. Message Board

robert.vince 73 posts  |  Last Activity: 23 hours ago Member since: Aug 30, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • robert.vince robert.vince 23 hours ago Flag

    I just got into it. Site seems fine.

  • Green PolkaDot Box Incorporated (GPDB) "GPDB" or "Company" announced today that T. Corl, one of its major investors and a principal in T&K Corl Investments, LLC, entered into an agreement with the Company to provide a million dollar credit line, increasing the Company's capacity to triple inventory levels in anticipation of increased sales.

    Due to its recent agreement with the world's leading online retailer and the pending launch of its national "Health Merchant" plan on December 1st, 2014, Green PolkaDot Box is preparing to sustain increasing sales by securing the credit line.

    "There were periods in our history when we were able to maintain 11% compounded monthly growth or more in sales and achieve higher value sales per order because we operated at full inventory," says GPDB CEO Rod Smith. "But in spite of our growth, in recent months, our operating deficits have eaten up the Company's working capital, making it difficult to sustain full inventory, resulting in a negative impact on sales and customer retention. This credit line will facilitate new growth and enable us to dedicate our other financial resources to achieve new strategic objectives."

    Green PolkaDot Box recently broke ground and installed anchor pins in preparation for erecting greenhouses for its first Living Produce Growing Center. Smith hopes to complete construction of this facility in early 2015. In addition, GPDB Management has identified a location for the establishment of its second distribution center in the eastern U.S., opening the way to reduce shipping times and ship frozen/refrigerated products to the customers of its retail marketing partners and GPDB members living in the east and Midwest, for the first time.

  • Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, disclosed today that it will provide Hemopurifier® therapy under FDA compassionate use access provisions to support potential requests by qualified physicians and institutes that may seek to treat ebola virus infection in the United States.
    The Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. At present, no antiviral therapy or vaccine has proven to be effective against Ebola virus infection in humans. According to the World Health Organization (WHO), nearly 5,000 deaths have been attributed to the current ebola virus epidemic.
    Based on guidance from FDA, the treatment of ebola virus infection provides for a unique circumstance where a physician or health care provider may wish to pursue the compassionate use of Hemopurifier® therapy based on the serious nature of the disease and absence of alternative therapies. Compassionate use provisions are typically approved by FDA on an individual patient basis, but may be expanded to include a small group.
    Aethlon also disclosed that it plans to submit its first ebola treatment data to the FDA as a means to support the goal of further expanding treatment access through emergency use regulatory pathways.

  • Starpharma Holdings Ltd is pleased to announce that the Company has been notified by its commercial partner, Ansell (ASX:ANN), that the VivaGel® condom is now available for purchase from Woolworths stores in Australia under Ansell’s brand, LifeStyles® Dual Protect™.

    The VivaGel® condom is a world-first product based on innovative Australian technology.

    LifeStyles® Dual Protect™ is the first condom with an antiviral agent. This ground-breaking product incorporates VivaGel® in the condom lubricant, in addition to providing physical barrier protection.

    Starpharma Chief Executive Officer, Dr Jackie Fairley, said:

    “It is terrific to see Dual Protect™ with VivaGel® on retail shelves in Australia. This product is a great example of a globally significant innovation developed and commercialised by two Australian companies. Consumer interest in the product has been high and the remarkable interest seen on social media bears this out.”

    The LifeStyles® Dual Protect™ condom lubricant contains VivaGel® (astodrimer sodium), the patented antiviral agent that has been shown in laboratory studies to achieve viral inactivation rates of up to 99.9%.
    LifeStyles® Dual Protect™ condoms carry the VivaGel® brand and Starpharma receives royalties based on sales.

  • Reply to

    Clinical Trial for Hep C link

    by toofadedtobeblue Oct 20, 2014 4:08 PM
    robert.vince robert.vince Oct 21, 2014 8:00 AM Flag

    It means that more data should be coming our way by end of July 2015 re hep C

  • Reply to

    AEMD ON CNN (VIDEO)

    by andy55q Oct 20, 2014 9:31 PM
    robert.vince robert.vince Oct 21, 2014 7:59 AM Flag

    No news yet. But when asked how AEMD got involved with the patient in Germany, Joyce said, 'They came to us" and mentioned that they were fully aware of their product.
    I think that's pretty significant as opposed to aemd begging them to try it.

  • Reply to

    AEMD ON CNN (VIDEO)

    by andy55q Oct 20, 2014 9:31 PM
    robert.vince robert.vince Oct 21, 2014 7:39 AM Flag

    they might not have mentioned the company, but they showed its filter which clearly showed the company name and website and contact info. It surely can't hurt, especially if people have a pause button on the remote for when the filter showed up. Filter appears at 1:45 into the video

  • Reply to

    trading halt?

    by onecrazytraderah Oct 17, 2014 10:23 AM
    robert.vince robert.vince Oct 17, 2014 1:17 PM Flag

    The halt if for the entire otc market, not aemd

  • Reply to

    everybody is selling

    by doncikas05 Oct 17, 2014 1:12 PM
    robert.vince robert.vince Oct 17, 2014 1:15 PM Flag

    Its not even down 2 percent, don't think everybody is selling

  • Reply to

    trading halt?

    by onecrazytraderah Oct 17, 2014 10:23 AM
    robert.vince robert.vince Oct 17, 2014 11:42 AM Flag

    There is no halt listed on the otcbb site

  • Yahoo finance won't let me post the link, but a Frankfurt newspaper originally wrote a story about the patient when he was admitted on October 3rd. He was very sick at the time. How sick? Here are a couple of statements from other articles about the patient:

    'On Thursday, the organizers of the flight had long feared, if the patient’s condition would permit even a transport to Germany.' From another article: 'Germany is prepared to treat its second Ebola patient, a hospital in Frankfurt has confirmed. Due to severe symptoms, however, it remained unclear when the patient would arrive.'

    The patient was admitted on October 3rd....
    Here is a statement from the article that I believe is blockbuster:

    'The man's health is "very serious but stable", said Timo Wolf, head of the infectious disease centre at Frankfurt University Hospital.
    The next three days will be decisive, he added, saying the treatment would last "two to three weeks".'

    Well it seems like we FLEW by the 'decisive' point which was on October 6th or so. Folks, its the 17th of October and this too sick to even fly guy is still kicking!

    Its time for Aethlon to Save the World!
    To the moon Alice.....

    Sentiment: Strong Buy

  • robert.vince robert.vince Oct 14, 2014 7:47 AM Flag

    Looks like Aethlon beat us to it:
    Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), announced today the first use of Hemopurifier® therapy on a patient infected with Ebola virus. The treatment was administered to a Ugandan doctor at the Frankfurt University Hospital in Germany. The patient, who is also a World Health Organization (WHO) worker, contracted the virus in Sierra Leone.

  • Reply to

    Ebola Announcement

    by robert.vince Oct 14, 2014 7:41 AM
    robert.vince robert.vince Oct 14, 2014 7:42 AM Flag

    To date, Hemopurifier therapy has been successfully administered in approximately one hundred treatment experiences in health compromised HIV and HCV infected individuals. These studies were conducted at the Apollo Hospital, Fortis Hospital, Sigma New Life Hospital, and the Medanta Medicity Institute, all located in India. In vitro validation studies that demonstrated the ability of the Hemopurifier to capture Zaire and other strains of ebola virus were conducted by researchers at the United States Army Medical Research Institute for Infectious Diseases (USAMRIID) and the United States Centers for Disease Control and Prevention (CDC).

  • Reply to

    Ebola Announcement

    by robert.vince Oct 14, 2014 7:41 AM
    robert.vince robert.vince Oct 14, 2014 7:41 AM Flag

    To date, Hemopurifier therapy has been successfully administered in approximately one hundred treatment experiences in health compromised HIV and HCV infected individuals. These studies were conducted at the Apollo Hospital, Fortis Hospital, Sigma New Life Hospital, and the Medanta Medicity Institute, all located in India. In vitro validation studies that demonstrated the ability of the Hemopurifier to capture Zaire and other strains of ebola virus were conducted by researchers at the United States Army Medical Research Institute for Infectious Diseases (USAMRIID) and the United States Centers for Disease Control and Prevention (CDC).

  • robert.vince by robert.vince Oct 14, 2014 7:41 AM Flag

    Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), announced today the first use of Hemopurifier® therapy on a patient infected with Ebola virus. The treatment was administered to a Ugandan doctor at the Frankfurt University Hospital in Germany. The patient, who is also a World Health Organization (WHO) worker, contracted the virus in Sierra Leone.
    The Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. At present, no antiviral therapy or vaccine has proven to be effective against Ebola virus infection in humans. The largest ebola virus epidemic in history is now spreading on a global basis with more than 4,000 deaths being reported by the WHO.
    "We thank the physicians in Frankfurt for allowing us the opportunity to treat this advanced-stage patient," stated Aethlon founder and CEO, Jim Joyce. "Details related to the patient's response to therapy will be disclosed once hospital officials deem it appropriate to report an update on the condition of this individual."
    In the care of ebola-infected individuals, the Hemopurifier targets two unmet medical needs: the rapid elimination of circulating ebola to inhibit continued progeny virus replication and the direct targeting of shed glycoproteins that overwhelm the host immune response. The device can be deployed for use within the global infrastructure of dialysis and CRRT machines already located in hospitals and clinics.
    Aethlon further disclosed that it is preparing to initiate U.S. clinical studies of Hemopurifier therapy based on the United States Food and Drug Administration's (FDA) approval of an Investigational Device Exemption (IDE) that was previously submitted by the Company. The study will contribute safety data to advance the device as a broad-spectrum countermeasure against pandemic threats, including ebola and chronic viral pathogens such as HIV and Hepatitis C (HCV).

  • Reply to

    TT034 HCV Trial Update

    by robert.vince Oct 10, 2014 7:27 AM
    robert.vince robert.vince Oct 10, 2014 7:27 AM Flag

    Dr Peter French, Managing Director and CEO commented, "Appointing Georgina to the position of Senior Drug Development Director is an important step for Benitec. She will work with the company and our clinical investigators to accelerate patient recruitment across all sites, and to ensure the trial progresses as rapidly as the guidelines allow."
    As any other material events occur relating to the trial, Benitec will provide updates to the market. Investors interested in tracking the progress of Benitec's TT-­‐034 trial should monitor progress via announcements lodged through the ASX.

  • robert.vince by robert.vince Oct 10, 2014 7:27 AM Flag

    HCV TRIAL UPDATE Sydney Australia, 8 October 2014: RNAi therapeutics company Benitec Biopharma Limited (ASX: BLT, OTC: BTEBY) provides an update regarding progress on the Company's US-­‐based, Phase I/IIa clinical trial for TT-­‐034, a ddRNAi-­‐based therapeutic, designed to treat and potentially cure hepatitis C (HCV) with a single injection.
    Benitec is pleased to report that the first patient dosed with TT-­‐034, continues to be monitored as per the protocol and that laboratory data indicate that the drug is well tolerated and safe at the dose administered. A second patient has been identified for dosing, and provided the patient continues to stay within the clinical parameters required by the trial protocol during the 28 day screening process, will be dosed as soon as possible following the completion of screening.
    The Company now has two trial sites on line, both of which are actively recruiting
    patients - Duke Clinical Research Centre and University of California San Diego.
    Since the last update, the Company has appointed US-­‐based Senior Drug Development Director, Georgina Kilfoil, with over 22 years in managing clinical trials and in clinical development to take responsibility for three main areas of activity aimed at increasing the rate of recruitment in the TT-­‐034 HCV trial. They are:
    • To liaise with the current trial sites to grow existing clinical trial site recruitment;
    • To advance negotiations with an additional five clinical trial sites in the US, and
    • Appoint specialized patient recruitment vendors across all trial sites

  • Reply to

    Ebola vaccine trials using KLH

    by a_sky_pilot Oct 7, 2014 9:13 PM
    robert.vince robert.vince Oct 8, 2014 9:01 AM Flag

    I see a .php and I'm thinking virus or malware for sure, so I tested the site first, it was safe, went to it, its legit.
    Nice find. BTW, how'd you get to post a link? Anytime I try it, it won't post my topic.

  • Reply to

    Stop it !!

    by sportacus95 Oct 7, 2014 10:45 AM
    robert.vince robert.vince Oct 7, 2014 2:01 PM Flag

    Ok, the company just announced it went bankrupt.... wheeeeee.... watch the share price soar now.
    (just kidding for those of you without a sarcastic sense of humor)

  • Reply to

    Dilution

    by chessen29 Sep 23, 2014 4:16 PM
    robert.vince robert.vince Oct 7, 2014 1:58 PM Flag

    Post the dilution link chessen, i like to be aware of good and bad, but as I'm sure you are well aware of, dilution occurs with even the best startup companies, its a way to keep them alive until they hit paydirt.
    And you can avoid the germs in the paydirt if you put on a vivagel condom now!

ALNY
93.43+1.90(+2.08%)12:22 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.